FierceBiotech Radio with NEA's Carol Gallagher

New Enterprise Associates Partner Carol Gallagher

New Enterprise Associates Partner Carol Gallagher joins FierceBiotech Radio to talk about her journey from Big Pharma to small biotech and eventually to venture capital, along the way shedding light on just what VCs do all day.

Download the episode on iTunes or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected] And if you missed last week's interview with Michael Gilman, CEO of the Atlas Venture-seeded Padlock Therapeutics, you can find it here.

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.